804 related articles for article (PubMed ID: 28978751)
1. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
2. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
3. In vitro toxicological support to establish specification limit for anti-CD3 monospecific impurity in a bispecific T cell engager drug, ERY974.
Harada A; Shioda A; Ikuno T; Iwata Y; Shiraiwa H; Wakabayashi T; Sano Y; Mishima M
Toxicol In Vitro; 2020 Aug; 66():104841. PubMed ID: 32247040
[TBL] [Abstract][Full Text] [Related]
4. Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells.
Iwata Y; Narushima Y; Harada A; Mishima M
Toxicol Appl Pharmacol; 2022 Apr; 441():115986. PubMed ID: 35304238
[TBL] [Abstract][Full Text] [Related]
5. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
6. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
7. Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Shiraiwa H; Narita A; Kamata-Sakurai M; Ishiguro T; Sano Y; Hironiwa N; Tsushima T; Segawa H; Tsunenari T; Ikeda Y; Kayukawa Y; Noguchi M; Wakabayashi T; Sakamoto A; Konishi H; Kuramochi T; Endo M; Hattori K; Nezu J; Igawa T
Methods; 2019 Feb; 154():10-20. PubMed ID: 30326272
[TBL] [Abstract][Full Text] [Related]
8. Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.
Sano Y; Azuma Y; Tsunenari T; Kayukawa Y; Shinozuka J; Fujii E; Amano J; Nishito Y; Maruyama T; Kinoshita Y; Sakamoto Y; Yoshida A; Miyazaki Y; Sato Y; Teramoto-Seida C; Ishiguro T; Tanaka T; Kitazawa T; Endo M
Nat Commun; 2022 Sep; 13(1):5265. PubMed ID: 36071036
[TBL] [Abstract][Full Text] [Related]
9. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
10. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
11. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
[TBL] [Abstract][Full Text] [Related]
12. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
13. Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial.
Komatsu SI; Kayukawa Y; Miyazaki Y; Kaneko A; Ikegami H; Ishiguro T; Nakamura M; Frings W; Ono N; Sakata K; Fujii T; Kishishita S; Kitazawa T; Endo M; Sano Y
Sci Rep; 2022 Jul; 12(1):12312. PubMed ID: 35853994
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
[TBL] [Abstract][Full Text] [Related]
15. Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma.
Yu L; Huang N; Sun H; Yang X; Fu Y; Lang Q; Wang J; Ge L
J Immunother; 2021 Apr; 44(3):106-113. PubMed ID: 33239522
[TBL] [Abstract][Full Text] [Related]
16. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
[TBL] [Abstract][Full Text] [Related]
17. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
18. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
19. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
[TBL] [Abstract][Full Text] [Related]
20. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
